BioCentury
ARTICLE | Clinical News

B244: Ph II started

December 21, 2016 10:20 PM UTC

AOBiome began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily B244 topical spray comprising 8×109 colony forming units (CFUs)/mL for 28 days in 116 patients....

BCIQ Company Profiles

AOBiome Therapeutics Inc.